Approximately 1,594,092 units of Camber Pharmaceuticals Valsartan (valsartan) tablets are being recalled because a carcinogen impurity was detected in the active ingredient used to manufacture the drug. This recall affects various dosages including 40 mg, 80 mg, 160 mg, and 320 mg strengths sold in 30-count and 90-count bottles. No specific injuries have been reported, but patients are advised to contact their doctor or pharmacist immediately as suddenly stopping blood pressure medication can pose health risks. These products were distributed nationwide to pharmacies and healthcare providers.
The medication contains an impurity classified as a probable human carcinogen, which may increase the risk of cancer with long-term exposure. Because this drug treats high blood pressure and heart failure, the risk of harm to the patient from suddenly stopping the medication may be greater than the risk posed by the impurity.
Pharmaceutical refund and medical consultation
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.